Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

MLA

Reck, Martin, et al. “Outcomes in Patients with Aggressive or Refractory Disease from REVEL: A Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer.” Lung Cancer (01695002), vol. 112, Oct. 2017, pp. 181–87. EBSCOhost, https://doi.org/10.1016/j.lungcan.2017.07.038.

APA

Reck, M., Pennell, N. A., Shepherd, F. A., Tsao, A., Thomas, M., Carter, G. C., Chan-Diehl, F., Alexandris, E., Lee, P., Zimmermann, A., Sashegyi, A., Pérol, M., Paz-Ares, L., Bidoli, P., Cappuzzo, F., Dakhil, S., Moro-Sibilot, D., Borghaei, H., Johnson, M., & Jotte, R. (2017). Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer (01695002), 112, 181–187. https://doi.org/10.1016/j.lungcan.2017.07.038

Chicago

Reck, Martin, Nathan A. Pennell, Frances A. Shepherd, Anne Tsao, Michael Thomas, Gebra Cuyun Carter, Faye Chan-Diehl, et al. 2017. “Outcomes in Patients with Aggressive or Refractory Disease from REVEL: A Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer.” Lung Cancer (01695002) 112 (October): 181–87. doi:10.1016/j.lungcan.2017.07.038.